Despite the frequent expression of EPO and EPOR in RCC, approximately 35% of RCC patients develop anaemia, whilst only 1-5% experience paraneoplastic polycythaemia[37,47,62,80-83]. This evidence concerns the gene EPO and renal cell carcinoma.